Another death mars AbbVie's latest batch of promising data for its star rheumatoid arthritis drug
AbbVie $ABBV is one step closer to achieving its goal of rolling out a closely-watched drug for rheumatoid arthritis as the third late-stage study in the program delivered another round of promising results. But it’s still being dogged by safety issues that may yet come back to haunt the effort.
Researchers say that the JAK-1 inhibitor upadacitinib (better known as ABT-494) handily beat out methotrexate as a monotherapy among patients who weren’t adequately responding to the standard generic. The key figures:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.